Last update Jan. 9, 2023

H01CC01

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Cetrorelix is a synthetic decapeptide antagonist of gonadorelin (gonadotropin-releasing hormone) that is used to prevent luteinizing hormone surges and premature ovulation in women undergoing ovarian stimulation treatment for assisted reproduction in cases of infertility. Subcutaneous administration.

At the date of the last update we did not find any published data on its excretion in breast milk.

Its pharmacokinetic data (high percentage of protein binding, high molecular weight and very wide volume of distribution) make it highly unlikely that significant quantities will pass into breast milk.

Its low oral bioavailability makes it difficult for it to pass to the infant’s plasma via ingested breast milk as, due to its protein nature, it degrades in the gastrointestinal tract and is not absorbed.


See below the information of this related product:

Alternatives

We do not have alternatives for H01CC01.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

H01CC01 is Ganirelix Acetate in ATC Code/s.

Is written in other languages:

Group

H01CC01 belongs to this group or family:

Tradenames

Main tradenames from several countries containing H01CC01 in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 0 %
Molecular weight 1.691 daltons
Protein Binding 82 %
VD 0.6 l/Kg
pKa 9.5 -
Tmax 1 - 2 hours
T½ 13 - 16 hours

References

  1. Merck. Ganirelix. Drug Summary. 2018 Full text (in our servers)
  2. Ganirelix Ficha técnica 2013 Full text (in our servers)
  3. Ganirelix Drug Summary 2013 Full text (in our servers)
  4. EMA. Ganirelix. Ficha técnica, 2010 Full text (in our servers)
  5. Oberyé JJ, Mannaerts BM, Kleijn HJ, Timmer CJ. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers. Fertil Steril. 1999 Abstract

Total visits

543

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM